These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 7981056)
1. DNA-targeted 2-nitroimidazoles: in vitro and in vivo studies. Cowan DS; Matejovic JF; McClelland RA; Rauth AM Br J Cancer; 1994 Dec; 70(6):1067-74. PubMed ID: 7981056 [TBL] [Abstract][Full Text] [Related]
2. Targeting radiosensitizers to DNA by attachment of an intercalating group: nitroimidazole-linked phenanthridines. Cowan DS; Panicucci R; McClelland RA; Rauth AM Radiat Res; 1991 Jul; 127(1):81-9. PubMed ID: 2068275 [TBL] [Abstract][Full Text] [Related]
3. DNA-targeted 2-nitroimidazoles: studies of the influence of the phenanthridine-linked nitroimidazoles, 2-NLP-3 and 2-NLP-4, on DNA damage induced by ionizing radiation. Buchko GW; Weinfeld M Radiat Res; 2002 Sep; 158(3):302-10. PubMed ID: 12175307 [TBL] [Abstract][Full Text] [Related]
4. Radiosensitizing and cytotoxic properties of DNA targeted phenanthridine-linked nitroheterocycles of varying electron affinities. Cowan DS; Matejovic JF; Wardman P; McClelland RA; Rauth AM Int J Radiat Biol; 1994 Dec; 66(6):729-38. PubMed ID: 7814971 [TBL] [Abstract][Full Text] [Related]
5. Mechanistic studies of enhanced in vitro radiosensitization and hypoxic cell cytotoxicity by targeting radiosensitizers to DNA via intercalation. Cowan DS; Kanagasabapathy VM; McClelland RA; Rauth AM Int J Radiat Oncol Biol Phys; 1992; 22(3):541-4. PubMed ID: 1735693 [TBL] [Abstract][Full Text] [Related]
6. NLP-1: a DNA intercalating hypoxic cell radiosensitizer and cytotoxin. Panicucci R; Heal R; Laderoute K; Cowan D; McClelland RA; Rauth AM Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1039-43. PubMed ID: 2703383 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. Hay MP; Wilson WR; Moselen JW; Palmer BD; Denny WA J Med Chem; 1994 Feb; 37(3):381-91. PubMed ID: 8308864 [TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of a cell line resistant to 5-[3-(2-nitro-1-imidazoyl)-propyl]-phenanthridinium bromide (2-NLP-3), a DNA-intercalating hypoxic cell radiosensitizer and cytotoxin. Cowan DS; McClelland RA; Rauth AM Biochem Pharmacol; 1995 Jun; 50(1):61-8. PubMed ID: 7605346 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers. Papadopoulou MV; Rosenzweig HS; Bloomer WD Bioorg Med Chem Lett; 2004 Mar; 14(6):1523-5. PubMed ID: 15006395 [TBL] [Abstract][Full Text] [Related]
12. Chromosome-damaging activity of a ruthenium radiosensitizer, RuCl2 (DMSO)2 (4-nitroimidazole)2, in Chinese hamster ovary cells in vitro. Chan PK; Skov KA; James BR; Farrell NP Chem Biol Interact; 1986 Oct; 59(3):247-54. PubMed ID: 3769054 [TBL] [Abstract][Full Text] [Related]
13. Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers. Bonnet M; Hong CR; Gu Y; Anderson RF; Wilson WR; Pruijn FB; Wang J; Hicks KO; Hay MP Bioorg Med Chem; 2014 Apr; 22(7):2123-32. PubMed ID: 24650701 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of some bioreducible 2-nitroimidazoles: comparison of in vitro cytotoxicity and ability to induce DNA strand breakage. O'Neill P; Jenkins TC; Stratford IJ; Silver AR; Ahmed I; McNeil SS; Fielden EM; Adams GE Anticancer Drug Des; 1987 Apr; 1(4):271-80. PubMed ID: 3450299 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins. Naylor MA; Stephens MA; Cole S; Threadgill MD; Stratford IJ; O'Neill P; Fielden EM; Adams GE J Med Chem; 1990 Sep; 33(9):2508-13. PubMed ID: 2391690 [TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships in the development of hypoxic cell radiosensitizers. III. Effects of basic substituents in nitroimidazole sidechains. Adams GE; Ahmed I; Clarke ED; O'Neill P; Parrick J; Stratford IJ; Wallace RG; Wardman P; Watts ME Int J Radiat Biol Relat Stud Phys Chem Med; 1980 Dec; 38(6):613-26. PubMed ID: 6970731 [TBL] [Abstract][Full Text] [Related]
17. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity. Oya N; Shibamoto Y; Sasai K; Shibata T; Murata R; Takagi T; Iwai H; Suzuki T; Abe M Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):119-27. PubMed ID: 7642409 [TBL] [Abstract][Full Text] [Related]
18. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Moselen JW; Hay MP; Denny WA; Wilson WR Cancer Res; 1995 Feb; 55(3):574-80. PubMed ID: 7834627 [TBL] [Abstract][Full Text] [Related]
19. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity. Zhang X; Su ZF; Ballinger JR; Rauth AM; Pollak A; Thornback JR Bioconjug Chem; 2000; 11(3):401-7. PubMed ID: 10821657 [TBL] [Abstract][Full Text] [Related]
20. A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170. Sasai K; Shibamoto Y; Takahashi M; Abe M; Wang J; Zhou L; Nishimoto S; Kagiya T Jpn J Cancer Res; 1989 Nov; 80(11):1113-8. PubMed ID: 2532634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]